RE:RE:RE:The competition had been launched! Where's Aristotle???OLDANUS007 is an uneducated "investor" with an obvious agenda.
From the GRAIL paper published in Nature Research journal back in 2018,
via a SPONSORED FEATURE (
Sponsor retains sole responsibility for the content of this article):
In the validation data set, the multi-cancer early detection test had a false positive rate of 0.7% and an overall test sensitivity (true positive rate) of 54.9% (95% confidence interval [CI]: 51.0–58.8%). Sensitivity and 95% CIs by stage for all cancer samples with known tumour stage were: stage I (n = 185), 18% (13–25%); stage II (n = 166), 43% (35–51%); stage III (n = 134), 81% (73–87%); and stage IV (n = 148), 93% (87–96%). TOO was predicted for 96% of samples with cancer; of those, the prediction was correct in 93%. TOO accuracy was not affected by cancer type or tumour stage. These results demonstrated that a targeted methylation-based multi-cancer early detection test using a machine-learning classifier can simultaneously detect more than 50 cancer types with a single, fixed, low false positive rate of less than 1%, and can accurately localise the TOO13.